Clinical Trials Logo

Filter by:
NCT ID: NCT05575167 Recruiting - Clinical trials for Osteoporosis, Postmenopausal

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

EURODEC
Start date: November 28, 2023
Phase:
Study type: Observational

A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab

NCT ID: NCT05575011 Recruiting - Healthy Volunteer Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115

Start date: October 10, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the safety and tolerability of single ascending dose of BIIB115 administered via intrathecal (IT) bolus injection to healthy male participants in Part A and multiple ascending doses of BIIB115 administered via IT bolus injection to pediatric Spinal Muscular Atrophy (SMA) participants previously treated with onasemnogene abeparvovec in Part B. The secondary objective of the study is to evaluate the pharmacokinetics (PK) of single-dose of BIIB115 administered via IT bolus injection to healthy male participants in Part A and multiple ascending doses of BIIB115 administered via IT bolus injection to pediatric SMA participants who previously received onasemnogene abeparvovec in Part B.

NCT ID: NCT05573555 Recruiting - Breast Cancer Clinical Trials

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Start date: March 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer. This study is seeking participants who have breast cancer that: - is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy - is sensitive to hormonal therapy (it is called estrogen receptor positive); and - is no longer responding to previous treatments This study is divided into separate sub-studies. For Sub-Study B: All participants will receive ARV-471 and a medicine called ribociclib. ARV-471 and ribociclib will be given at the same time by mouth, at home, 1 time a day. The experiences of people receiving the study medicine will be examined. This will help determine if the study medicine is safe and effective. Participants will continue to take ARV-471 and ribociclib until their cancer is no longer responding, or side effects become too severe. They will have visits at the study clinic about every 4 weeks.

NCT ID: NCT05572710 Recruiting - Clinical trials for Aortic Valve Stenosis

Avalus European Registry - an Observational Study to Evaluate Safety and Efficacy in a Real World Population

Avalus
Start date: June 10, 2020
Phase:
Study type: Observational [Patient Registry]

This is a prospective, observational, single-arm, multi-center registry of patients undergoing bioprosthetic aortic valve replacement with the Avalus valve. This prospective registry aims to examine the outcome and performance of surgical aortic valve replacement with the Avalus pericardial bioprosthesis.

NCT ID: NCT05572515 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

MajesTEC-9
Start date: March 29, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.

NCT ID: NCT05572346 Recruiting - Obesity Clinical Trials

Digital App for Telerehabilitation in Respiratory Diseases

Start date: October 17, 2022
Phase:
Study type: Observational

The purpose of this study is to evaluate the feasibility and the mid-term effects of a pulmonary rehabilitation intervention, delivered by digital App, on quality of life of patients affected by respiratory diseases. The App will include a monitored exercise training program based on most recent cardiopulmonary rehabilitation guidelines, including alerts, reminders and educational contents as well as chat and online visits with healthcare professionals to improve patient engagement.

NCT ID: NCT05572320 Recruiting - Stroke, Acute Clinical Trials

Platelet Function and Neurological Events

MULTINEUR
Start date: October 10, 2022
Phase:
Study type: Observational

Several studies have shown an association between platelet function and stroke in patients undergoing carotid thromboendarterectomy (TEA). The present study will assess the correlation between platelet function evaluated by the impedance aggregometry and neurological events in patients undergoing carotid TEA.

NCT ID: NCT05570682 Recruiting - Anesthesia Clinical Trials

Manually Controlled Infusion vs Target Controlled Infusion for StrokeThrombectomy

HASTE
Start date: October 9, 2022
Phase: N/A
Study type: Interventional

The goal of this randomized controlled trial is to compare manual general anesthesia induction to general anesthesia induction guided by target controlled infusion system in cerebral ischemic stroke The main questions it aims to answer are: - Does target controlled infusion has a more favorauble hemodynamic profile than manual general anesthesia induction? - Do patients receiving general anesthesia with target controlled infusion system have a more favourable outcome? Participants will receive general anesthesia induction with a target controlled infusion system and will be compared to patients receiving manual general anesthesia induction.

NCT ID: NCT05570149 Recruiting - Migraine Disorders Clinical Trials

EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.

EMBRACE
Start date: January 1, 2023
Phase:
Study type: Observational [Patient Registry]

The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.

NCT ID: NCT05570058 Recruiting - Fibrosis Clinical Trials

Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Start date: September 8, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.